Crop Life Science Limited (NSE:CLSL)
India · Delayed Price · Currency is INR 47.00
0.00 (0.00%)
Feb 13, 2026, 12:37 PM IST
Crop Life Science Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 2,145 | 2,006 | 1,986 | 1,312 | 1,020 | 1,189 |
Other Revenue | - | - | - | 0 | - | - |
| 2,145 | 2,006 | 1,986 | 1,312 | 1,020 | 1,189 | |
Revenue Growth (YoY) | 3.40% | 1.00% | 51.35% | 28.64% | -14.23% | -11.99% |
Cost of Revenue | 1,538 | 1,422 | 1,467 | 925.23 | 598.3 | 683.04 |
Gross Profit | 607.66 | 583.65 | 518.88 | 387.03 | 421.8 | 506.26 |
Selling, General & Admin | 163.57 | 147.03 | 141.94 | 128.52 | 135.52 | 135.65 |
Other Operating Expenses | 283.75 | 271.99 | 250.67 | 138.57 | 208.93 | 278.79 |
Operating Expenses | 494.39 | 467.28 | 424.88 | 304.15 | 366.96 | 442.48 |
Operating Income | 113.27 | 116.37 | 94 | 82.88 | 54.84 | 63.78 |
Interest Expense | -49.15 | -43.86 | -29.03 | -30.7 | -19.54 | -17.66 |
Interest & Investment Income | 3.75 | 3.75 | 13.34 | 5.34 | 0.11 | 0.1 |
Currency Exchange Gain (Loss) | 3 | 3 | - | 0.28 | 0.54 | 0.13 |
Other Non Operating Income (Expenses) | 4.41 | -2.66 | -2.51 | -1.82 | 1.34 | 2.36 |
EBT Excluding Unusual Items | 75.28 | 76.6 | 75.8 | 55.97 | 37.28 | 48.7 |
Gain (Loss) on Sale of Assets | 1.35 | 1.35 | 5.03 | - | 0.4 | 0.55 |
Other Unusual Items | 2.96 | - | 0.24 | - | 0 | - |
Pretax Income | 79.6 | 77.96 | 81.07 | 55.97 | 37.69 | 49.25 |
Income Tax Expense | 23.29 | 21.95 | 20.91 | 15.26 | 9.55 | 12.21 |
Earnings From Continuing Operations | 56.31 | 56.01 | 60.16 | 40.71 | 28.14 | 37.05 |
Minority Interest in Earnings | 1.92 | 2.91 | 0.08 | - | - | - |
Net Income | 58.24 | 58.92 | 60.23 | 40.71 | 28.14 | 37.05 |
Net Income to Common | 58.24 | 58.92 | 60.23 | 40.71 | 28.14 | 37.05 |
Net Income Growth | 7.08% | -2.19% | 47.95% | 44.67% | -24.04% | 14.69% |
Shares Outstanding (Basic) | 14 | 17 | 17 | 12 | 12 | 12 |
Shares Outstanding (Diluted) | 14 | 17 | 17 | 12 | 12 | 12 |
Shares Change (YoY) | -5.02% | - | 42.83% | - | - | - |
EPS (Basic) | 4.13 | 3.44 | 3.51 | 3.39 | 2.35 | 3.09 |
EPS (Diluted) | 4.13 | 3.44 | 3.51 | 3.39 | 2.35 | 3.09 |
EPS Growth | 12.74% | -2.19% | 3.66% | 44.56% | -24.04% | 14.77% |
Free Cash Flow | -139.97 | -60.02 | -157.73 | -27.42 | -45.13 | 8.67 |
Free Cash Flow Per Share | -9.92 | -3.50 | -9.20 | -2.29 | -3.76 | 0.72 |
Gross Margin | 28.32% | 29.10% | 26.13% | 29.49% | 41.35% | 42.57% |
Operating Margin | 5.28% | 5.80% | 4.73% | 6.32% | 5.38% | 5.36% |
Profit Margin | 2.71% | 2.94% | 3.03% | 3.10% | 2.76% | 3.12% |
Free Cash Flow Margin | -6.52% | -2.99% | -7.94% | -2.09% | -4.42% | 0.73% |
EBITDA | 154.74 | 154.23 | 126.82 | 106.71 | 73.09 | 85.34 |
EBITDA Margin | 7.21% | 7.69% | 6.39% | 8.13% | 7.17% | 7.17% |
D&A For EBITDA | 41.47 | 37.86 | 32.82 | 23.83 | 18.25 | 21.56 |
EBIT | 113.27 | 116.37 | 94 | 82.88 | 54.84 | 63.78 |
EBIT Margin | 5.28% | 5.80% | 4.73% | 6.32% | 5.38% | 5.36% |
Effective Tax Rate | 29.26% | 28.15% | 25.80% | 27.26% | 25.33% | 24.78% |
Revenue as Reported | 2,163 | 2,016 | 2,007 | 1,320 | 1,024 | 1,195 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.